|Positive WB detected in||human placenta tissue|
|Positive IP detected in||Jurkat cells|
|Positive IHC detected in||human heart tissue, human lymphoma tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||Jurkat cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:100-1:400|
|Sample-dependent, check data in validation data gallery|
14745-1-AP targets ACVRL1 in WB, IP, IHC, FC, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Rabbit / IgG|
|Immunogen||ACVRL1 fusion protein Ag6449|
|Full Name||activin A receptor type II-like 1|
|Calculated molecular weight||56 kDa|
|Observed molecular weight||63 kDa|
|GenBank accession number||BC042637|
|Gene ID (NCBI)||94|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
ACVRL1 (also known as ALK1) is a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. ACVRL1 is highly expressed in endothelial cells and has a critical role in the control of blood vessel development and repair (PMID: 8640225). Mutations in the ACVRL1 gene are associated with hemorrhagic telangiectasia type 2.
|Product Specific Protocols|
|WB protocol for ACVRL1 antibody 14745-1-AP||Download protocol|
|IHC protocol for ACVRL1 antibody 14745-1-AP||Download protocol|
|IP protocol for ACVRL1 antibody 14745-1-AP||Download protocol|
|FC protocol for ACVRL1 antibody 14745-1-AP||Download protocol|
|Click here to view our Standard Protocols|
J Thorac Dis
Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: differential diagnosis based on a case series.
Cell Biol Int
CHRDL2 promotes osteosarcoma cell proliferation and metastasis through the BMP-9/ PI3K/ AKT pathway.
J Mol Cell Cardiol
BMP9 attenuates occurrence of venous malformation by maintaining endothelial quiescence and strengthening vessel walls via SMAD1/5/ID1/α-SMA pathway.